CR20110640A - Derivados de amiloide p sérico/de suero y su preparación y uso - Google Patents

Derivados de amiloide p sérico/de suero y su preparación y uso

Info

Publication number
CR20110640A
CR20110640A CR20110640A CR20110640A CR20110640A CR 20110640 A CR20110640 A CR 20110640A CR 20110640 A CR20110640 A CR 20110640A CR 20110640 A CR20110640 A CR 20110640A CR 20110640 A CR20110640 A CR 20110640A
Authority
CR
Costa Rica
Prior art keywords
sérico
serero
amiloid
derivatives
preparation
Prior art date
Application number
CR20110640A
Other languages
English (en)
Inventor
W Scott Willett
Richard J Caimi
Original Assignee
Promedior Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promedior Inc filed Critical Promedior Inc
Publication of CR20110640A publication Critical patent/CR20110640A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un aspecto de la presente invención se refiere al sorprendente descubrimiento de que la modificación de una estructura de glicanos de un polipéptido SAP puede aumentar la actividad biológica en relación a una muestra de SAP de tipo salvaje aislado de suero humano. La divulgación proporciona tanto polipéptidos SAP humanos variantes y los métodos para hacer la misma.
CR20110640A 2009-06-04 2011-11-29 Derivados de amiloide p sérico/de suero y su preparación y uso CR20110640A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21793109P 2009-06-04 2009-06-04

Publications (1)

Publication Number Publication Date
CR20110640A true CR20110640A (es) 2012-01-30

Family

ID=43298203

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110640A CR20110640A (es) 2009-06-04 2011-11-29 Derivados de amiloide p sérico/de suero y su preparación y uso

Country Status (27)

Country Link
US (5) US9296800B2 (es)
EP (2) EP3042915B1 (es)
JP (3) JP5801293B2 (es)
CN (1) CN102574902B (es)
AU (1) AU2010256426B2 (es)
BR (2) BRPI1012924B8 (es)
CA (1) CA2764461C (es)
CO (1) CO6480917A2 (es)
CR (1) CR20110640A (es)
CY (1) CY1120817T1 (es)
DK (2) DK2438083T3 (es)
EA (1) EA030332B1 (es)
ES (2) ES2692815T3 (es)
HR (2) HRP20160221T1 (es)
HU (1) HUE026737T2 (es)
IL (1) IL216744A (es)
LT (1) LT3042915T (es)
MX (1) MX2011012738A (es)
MY (1) MY158761A (es)
NZ (1) NZ596849A (es)
PL (2) PL3042915T3 (es)
PT (1) PT3042915T (es)
SI (2) SI3042915T1 (es)
TR (1) TR201815592T4 (es)
UA (1) UA110323C2 (es)
WO (1) WO2010141918A1 (es)
ZA (1) ZA201108857B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5220025B2 (ja) * 2006-12-04 2013-06-26 プロメディオール， インコーポレイテッド 線維症疾患を処置するための併用療法
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
PT2405929T (pt) * 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) * 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
FR2969153B1 (fr) * 2010-12-17 2014-10-17 Lab Francais Du Fractionnement Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee
DK2709619T3 (en) * 2011-05-16 2018-01-15 Cellceutix Corp RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS
WO2013096847A1 (en) * 2011-12-21 2013-06-27 Promedior, Inc. Serum amyloid p-antibody fusion proteins
RU2020111934A (ru) 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
CN105372214B (zh) * 2014-08-18 2019-06-28 中国科学院上海有机化学研究所 一种鉴定新红细胞生成刺激蛋白的n-连接寡糖结构的方法
KR20190045350A (ko) * 2016-09-13 2019-05-02 바이엘 헬스케어 엘엘씨 인자 VIIa 당형태
JP6852397B2 (ja) * 2016-12-28 2021-03-31 株式会社島津製作所 分析用試料の調製方法および分析方法
CN108114001B (zh) * 2017-12-23 2023-05-30 中国科学院海洋研究所 一种诱导海产双壳贝类产卵的诱导剂及其应用方法
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
BR112023008317A2 (pt) * 2020-11-02 2024-02-06 Attralus Inc Proteínas de fusão sap fc e métodos de uso

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1562244A (en) 1976-11-11 1980-03-05 Lock P M Wound dressing materials
GB1594389A (en) 1977-06-03 1981-07-30 Max Planck Gesellschaft Dressing material for wounds
GB8516081D0 (en) 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
US6071517A (en) 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
DE3880647T2 (de) 1987-11-20 1993-11-18 Kanegafuchi Chemical Ind Sorbentmittel für Serum-Amyloid-Proteine.
US7070994B2 (en) 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5092876A (en) 1989-08-30 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Cell attachment peptides derived from amyloid P component
WO1992021364A1 (en) 1991-05-31 1992-12-10 New England Deaconess Hospital Corporation Cea-binding proteins and methods for their isolation and use
US5591709A (en) 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US6054121A (en) 1993-02-26 2000-04-25 The Picower Institute For Medical Research Modulation of immune responses in blood-borne mesenchymal cells
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5804446A (en) 1993-02-26 1998-09-08 The Picower Institute For Medical Research Blood-borne mesenchymal cells
AU7043694A (en) 1993-05-27 1994-12-20 Regents Of The University Of Michigan, The Method of treatment and prevention of immune complex-induced lung injury
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9317120D0 (en) 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5981470A (en) 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
US5989811A (en) 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5922577A (en) 1995-04-11 1999-07-13 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US5876980A (en) 1995-04-11 1999-03-02 Cytel Corporation Enzymatic synthesis of oligosaccharides
US6030815A (en) 1995-04-11 2000-02-29 Neose Technologies, Inc. Enzymatic synthesis of oligosaccharides
US5728554A (en) 1995-04-11 1998-03-17 Cytel Corporation Enzymatic synthesis of glycosidic linkages
WO1997010341A1 (en) * 1995-09-13 1997-03-20 Fuji Yakuhin Kogyo Kabushiki Kaisha D-pantolactone hydrolase and gene encoding the same
US5750345A (en) 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
AU712819B2 (en) 1996-01-25 1999-11-18 Profylakse Aps Pharmaceutical composition comprising serum amyloid P component for proph ylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
AU8525098A (en) 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
US6365570B1 (en) * 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
CA2321136A1 (en) 1998-02-17 1999-08-19 Medarex, Inc. Treating and diagnosing macrophage-mediated diseases using fc receptor ligands
CN1235559C (zh) 1998-03-11 2006-01-11 株式会社创研 皮肤水分保持能力的改善剂
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
JPH11319542A (ja) 1998-05-08 1999-11-24 Tokuyama Corp 超薄層の製造方法
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6600019B2 (en) 2000-01-06 2003-07-29 Curagen Corporation Polypeptides and nucleic acids encoding same
WO2001074300A1 (en) 2000-03-30 2001-10-11 Brennen Medical, Inc. Anti-microbial and immunostimulating composition
US20040068095A1 (en) 2001-03-14 2004-04-08 Shimkets Richard A. Novel human proteins, polynucleotides encoding them and methods of using the same
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6872541B2 (en) 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US6537811B1 (en) 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US20030199442A1 (en) 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2004049214A (ja) 2001-11-29 2004-02-19 Nippon Shokubai Co Ltd 蛋白質またはペプチドの細胞内導入方法
US7022476B2 (en) 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
GB0211136D0 (en) 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
KR20100137026A (ko) 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
JP4922560B2 (ja) 2002-12-23 2012-04-25 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞への分化の検出方法、線維症を抑制する組成物および方法
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
EP1597281A1 (en) 2003-02-27 2005-11-23 TheraVision GmbH Method for reducing levels of c-reactive protein
EP1747237A4 (en) 2004-04-16 2008-05-21 Macrogenics Inc SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
US7378504B2 (en) 2004-06-03 2008-05-27 Medarex, Inc. Human monoclonal antibodies to Fc gamma receptor I (CD64)
WO2006002930A2 (en) 2004-06-30 2006-01-12 Friedrich-Alexander- Universitaet Erlangen- Nuernberg FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS
NZ553118A (en) 2004-09-02 2009-12-24 Genentech Inc Anti-FC-gamma RIIB receptor antibody and uses therefor
AU2005286763A1 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical, Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP1846454A2 (en) 2004-09-30 2007-10-24 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor ii (cd32)
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2007047796A2 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070243163A1 (en) 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
JP5220025B2 (ja) 2006-12-04 2013-06-26 プロメディオール， インコーポレイテッド 線維症疾患を処置するための併用療法
WO2009009034A2 (en) 2007-07-06 2009-01-15 Promedior, Inc Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
PT2405929T (pt) 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
AU2010232591A1 (en) 2009-04-01 2011-11-03 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid P
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk

Also Published As

Publication number Publication date
US20210179679A1 (en) 2021-06-17
LT3042915T (lt) 2018-11-12
US20200369735A1 (en) 2020-11-26
US20180044387A1 (en) 2018-02-15
JP5801293B2 (ja) 2015-10-28
EA201171490A1 (ru) 2012-05-30
JP2017082008A (ja) 2017-05-18
CN102574902B (zh) 2016-01-20
EA030332B1 (ru) 2018-07-31
BR122020010980B1 (pt) 2021-07-06
US20100317596A1 (en) 2010-12-16
JP2012529429A (ja) 2012-11-22
US9296800B2 (en) 2016-03-29
SI2438083T1 (sl) 2016-04-29
EP3042915B1 (en) 2018-08-08
TR201815592T4 (tr) 2018-11-21
NZ596849A (en) 2013-08-30
CO6480917A2 (es) 2012-07-16
AU2010256426A1 (en) 2012-01-12
ZA201108857B (en) 2018-11-28
BRPI1012924A2 (pt) 2016-04-05
PL3042915T3 (pl) 2019-01-31
PL2438083T3 (pl) 2016-06-30
CA2764461A1 (en) 2010-12-09
ES2563748T3 (es) 2016-03-16
EP3042915A1 (en) 2016-07-13
ES2692815T3 (es) 2018-12-05
HK1168603A1 (zh) 2013-01-04
MY158761A (en) 2016-11-15
CN102574902A (zh) 2012-07-11
IL216744A0 (en) 2012-02-29
JP2015120754A (ja) 2015-07-02
DK2438083T3 (en) 2016-03-07
HUE026737T2 (en) 2016-07-28
UA110323C2 (en) 2015-12-25
EP2438083A4 (en) 2012-11-21
PT3042915T (pt) 2018-10-18
WO2010141918A9 (en) 2013-03-28
BRPI1012924B1 (pt) 2020-12-22
MX2011012738A (es) 2012-02-21
HRP20181803T1 (hr) 2018-12-28
DK3042915T3 (en) 2018-11-05
CA2764461C (en) 2021-05-04
EP2438083B1 (en) 2015-12-02
BRPI1012924B8 (pt) 2021-05-25
SI3042915T1 (sl) 2018-12-31
EP2438083A1 (en) 2012-04-11
AU2010256426B2 (en) 2016-03-31
IL216744A (en) 2016-09-29
CY1120817T1 (el) 2019-12-11
HRP20160221T1 (hr) 2016-03-25
US20230058309A1 (en) 2023-02-23
WO2010141918A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
CO6390023A2 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de las celulas t
CL2012001030A1 (es) Polipeptido inmunomodulador derivado de la il-2 que comprende varias mutaciones respecto a la secuencia de il-2 nativa que inhibe preferencialmente la actividad de il- 2 sobre celulas t reguladoras in vitro; proteína de fusión que lo comprende; y su uso para tratar cancer.
CO6480917A2 (es) Derivados de suero amiloide p, su preparación y uso.
BR112013018399A2 (pt) anticorpos anti-il1rap e seus usos para tratamento humano
CL2011000086A1 (es) Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b.
MX2012004868A (es) Proteinas de enlace al antigeno il-23 humanas.
CR20110470A (es) Proteínas de union a il-17
CL2013001107A1 (es) Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
ECSP13012440A (es) Anticuerpos anti-fap y métodos de uso
SMT201700006B (it) Analoghi della triazina e uso di essi come agenti terapeutici e sonde diagnostiche
BRPI1009413A2 (pt) emulsões e adesivos contendo proteína e produção e uso dos mesmos
GT201200189A (es) Antagonistas de pcsk9
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
ECSP12012307A (es) Proteínas de unión a il-1
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
PL3756657T3 (pl) Preparaty peptydu n-końcowego aneksyny a1 i sposoby
MX382826B (es) Anticuerpos dkk1 y metodos de uso.
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
CR20120026A (es) Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv
EA201171494A1 (ru) Миметики белка smac
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
BRPI1014544A8 (pt) anticorpos anti-il-17f e metodos de uso dos mesmos
BR112014011217A2 (pt) substrato de polipeptídeo isolado, substrato de polipeptídeo adamts13, substrato de polipeptídeo liofilizado, método para clivar o substrato de polipeptídeo adamts13, método para medir a atividade de adamts13 em uma amostra, método para medida quantitativa da atividade da protease adamts13, kit para teste in vitro da atividade adamts13 em um indivíduo e uso do substrato de polipeptídeo adamts13
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
ECSP13012536A (es) Composiciones de anticuerpo y métodos de uso